NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/04/2024
Back to search
Official data from USPTO
RESOLIAN BIOANALYTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RESOLIAN BIOANALYTICS
ST13
US500000097796233Class
42
Filing
97796233
Registration
7410178
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
06/04/2024
Trademark type
Word
Nice classes
42
Filing date
02/15/2023
Registration date
06/04/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/04/2024
Last transaction
06/04/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/17/2023
First use in commerce
05/17/2023
Drawing code
4
Owner type
03
Owner location
Malvern, PA
Examiner
DONEGAN, DANIEL
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Alliance Pharma Inc.
Representatives
Christopher D. Olszyk, Jr. FOX ROTHSCHILD LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Laboratory testing services in clinical research and clinical trials of innovator and generic medicines in the pharmaceutical and biotechnology fields; Research and development in the fields of bioanalysisimmunoassay developmentbioanalytical assay validation and testingbiomarker studiesdrug metabolismpharmacokinetic testing; Pharmaceutical research and development services; Chemicalbioanalyticalbiological and biotechnology research services; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Pharmaceutical drug development services; Scientific testing in the fields of oncologyneurologygastroenterologyimmunologyendocrinologygene therapyinfectious diseaserare and orphan diseasescardiovascular diseasemetabolic diseasecentral nervous systemophthalmologyrespiratory diseasesfor medical and pharmaceutical research purposes; Drug and chemical materials analysis servicesquality evaluation and analysisquality assurancequality controlin the fields of pharmaceuticalbiopharmaceuticalbiotechnology and medical device development; Scientific analytical laboratory services; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of pharmaceutical drugpharmaceutical excipientconsumer healthcare chemical development; ChemistryManufacturingControls (CMC) laboratory and stability testing and analytical services in the fields of pharmaceutical drugpharmaceutical excipientconsumer healthcare chemical development; Analytical servicesproviding Good Laboratory Practices (GLP) testing and quality assurance services to assess clinical performance in the field of therapeutic drug evaluation and development
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/04/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/30/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/30/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/19/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/19/2024
IUAF
USE AMENDMENT FILED
04/01/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/01/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/09/2024
PUBO
PUBLISHED FOR OPPOSITION
01/09/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/20/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/29/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/28/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/28/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/14/2023
GNRT
NON-FINAL ACTION E-MAILED
11/14/2023
CNRT
NON-FINAL ACTION WRITTEN
11/14/2023
DOCK
ASSIGNED TO EXAMINER
11/14/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/06/2023
NWAP
NEW APPLICATION ENTERED
02/18/2023
Continuous trademark protection
Get notified about every new filing that threatens RESOLIAN BIOANALYTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.